| # | Country | Total Patents | |
|---|---|---|---|
| #1 | Australia | 14 | |
| #2 | United States | 10 | |
| #3 | EPO (European Patent Office) | 8 | |
| #4 | Republic of Korea | 8 | |
| #5 | Canada | 7 | |
| #6 | Israel | 7 | |
| #7 | Singapore | 5 | |
| #8 | Brazil | 3 | |
| #9 | Chile | 1 | |
| #10 | China | 1 | |
| #11 | Japan | 1 | |
| #12 | Mexico | 1 |
| # | Industry | |
|---|---|---|
| #1 | Pharmaceuticals | |
| #2 | Biotechnology | |
| #3 | Measurement |
| # | Technology | |
|---|---|---|
| #1 | Peptides | |
| #2 | Therapeutic chemical compounds | |
| #3 | Medical preparations | |
| #4 | Analysing materials | |
| #5 | Microorganisms |
| # | Name | Total Patents |
|---|---|---|
| #1 | Wang Zhengyi | 49 |
| #2 | Guo Bingshi | 49 |
| #3 | Fang Lei | 48 |
| #4 | Zang Jingwu | 37 |
| #5 | Wang Yongqiang | 14 |
| #6 | Cui Feifei | 12 |
| #7 | Cao Wei | 12 |
| #8 | Gu Haijuan | 10 |
| #9 | Yang Qiumei | 7 |
| #10 | Lei Fang | 4 |
| Publication | Filing date | Title |
|---|---|---|
| AU2020261961A1 | Human PD-L1 antibodies | |
| CA3107369A1 | Novel cd47 antibodies and methods of using same | |
| AU2019342180A1 | Anti-CXCL13 antibodies for treating autoimmune diseases and cancer | |
| CA3097443A1 | Fusion proteins containing cd47 antibodies and cytokines | |
| EP3568417A1 | Anti-pd-l1 antibody and il-7 fusions | |
| AU2019203917A1 | Modified CK and CH1 domains | |
| KR20210007041A | Anti-gm-csf antibodies and uses thereof |